Preclinical Imaging Market by Product (Reagents, Software & Services), Type (Multimodal Systems, Standalone Imaging Systems), Imaging Modality, Applications, End Users - Global Forecast 2025-2032
Description
The Preclinical Imaging Market was valued at USD 4.25 billion in 2024 and is projected to grow to USD 4.75 billion in 2025, with a CAGR of 11.99%, reaching USD 10.52 billion by 2032.
Comprehensive orientation to the contemporary preclinical imaging ecosystem highlighting technological convergence and application-driven demand
Preclinical imaging sits at the intersection of biological discovery and instrumentation innovation, serving as a foundational pillar for translational research. Advances in imaging reagents, multimodal and standalone systems, and analytical software have expanded the capacity to visualize complex biological processes noninvasively, thereby accelerating candidate selection in drug development and refining mechanistic studies across immunology, oncology, neurology, and infectious disease research.
The field has matured from isolated modality deployments to integrated workflows in which reagents and imaging platforms are co-optimized for sensitivity, specificity, and throughput. Progressive improvements in tracer chemistry, contrast agent specificity, and image-analysis algorithms have reduced ambiguity in preclinical endpoints, enabling clearer correlations between molecular events and phenotypic outcomes. Consequently, stakeholders across academic research, contract research organizations, and industry laboratories are adapting procurement and study-design practices to extract maximum interpretive value from imaging datasets.
This report frames the contemporary preclinical imaging landscape with an emphasis on technological evolution, application-driven demands, and the operational implications for end users. The narrative avoids speculative projections, focusing instead on the observable shifts in capability and adoption that are influencing capital investment, reagent selection, and platform deployment strategies.
Emergence of integrated multimodal systems and data-driven workflows reshaping how preclinical imaging platforms and reagents are deployed
The preclinical imaging landscape is undergoing transformative shifts driven by technological convergence, data-centric workflows, and evolving end-user expectations. Multimodal integration is replacing single-modality paradigms, as researchers demand concurrent anatomical, functional, and molecular information to derive richer biological insights. This trend is supported by enhancements in core imaging modalities as well as improvements in reagents and analytical software, which together increase sensitivity and reduce interpretative uncertainty.
Simultaneously, there is a discernible shift toward modular and scalable systems that accommodate variable throughput and diverse study designs. Standalone imaging platforms remain important for focused applications, but the value proposition of multimodal systems is amplified when combined with advanced image-processing pipelines and reagent chemistries that enable cross-validation of signals. Furthermore, the proliferation of open-source and commercial software tools for image quantification and data management has elevated expectations for interoperability and reproducibility across laboratories.
Operationally, these shifts are influencing procurement cycles, study design, and collaborative models. Contract research organizations and academic cores are adapting service offerings to meet demand for integrated imaging solutions, while pharmaceutical and biotechnology companies increasingly emphasize translational fidelity in preclinical studies. The cumulative effect is a more interconnected, software-enabled imaging ecosystem that prioritizes data quality, workflow efficiency, and translational relevance.
Trade policy adjustments in 2025 influencing procurement strategies and supply chain resilience across the preclinical imaging value chain
The policy environment affecting preclinical research tools has become more intricate as trade measures and tariff schedules evolve, creating tangible implications for procurement planning and supply chain strategy. Tariff changes implemented in 2025 have altered cost structures for internationally sourced instruments and reagents, prompting laboratories and institutional buyers to reassess supplier relationships and total cost of ownership considerations.
In response to these adjustments, procurement teams are prioritizing supply chain resilience and inventory strategies to mitigate the timing and price impacts of cross-border trade measures. Vendors have likewise adjusted commercial terms, expanding regional distribution, local service footprints, and stocking arrangements to maintain competitiveness. These shifts have reinforced the importance of flexible sourcing, contractual clarity on freight and customs responsibilities, and proactive supplier risk assessment as part of capital-equipment and consumables planning.
From a strategic perspective, research organizations are balancing short-term operational continuity with longer-term considerations about localization of supply and investment in serviceable systems. The net effect is a heightened focus on supplier diversification, contractual protections, and collaborative logistics planning to preserve study timelines and maintain access to specialized reagents and instrumentation despite evolving trade conditions.
Multidimensional segmentation framework linking reagent classes, system architectures, imaging modalities, applications, and end-user requirements for strategic alignment
Detailed segmentation illuminates where value and demand converge across product, system type, imaging modality, application, and end-user profiles, enabling stakeholders to align technology choices with scientific objectives. Product-level distinctions separate reagents from software and services, with reagents encompassing bioluminescent imaging reagents, fluorescent imaging reagents, MRI contrasting reagents, PET radioactive tracers, ultrasound contrasting reagents, and X-ray CT contrasting reagents, while software and services include image analysis platforms, data management solutions, and validation services that support reproducible workflows.
System-type segmentation differentiates multimodal systems from standalone imaging systems, underscoring decisions that hinge on throughput, spatial resolution, and the necessity for correlative measurements. Imaging modality segmentation covers magnetic particle imaging, magnetic resonance imaging, micro-computed tomography, optical imaging, positron emission tomography, and single-photon emission computed tomography, each offering distinct strengths in sensitivity, spatial resolution, and target specificity that inform assay selection and study design. Application-based segmentation highlights core scientific domains-cardiology, drug development, immunology and inflammation, infectious diseases, neurology, and oncology-where imaging contributes to endpoint definition, safety profiling, and mechanism-of-action elucidation.
End-user segmentation captures the diversity of institutional needs across academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies, reflecting differences in procurement cycles, service expectations, and demands for regulatory alignment. Taken together, these segmentation lenses provide a multi-dimensional framework for mapping technology capabilities to specific experimental goals, enabling purchasers and innovators to prioritize investments that deliver operational and scientific impact.
Regional dynamics and operational considerations shaping adoption patterns and vendor engagement strategies across global preclinical imaging markets
Regional dynamics shape adoption patterns, investment priorities, and vendor strategies within the preclinical imaging landscape, driven by differences in research funding models, regulatory environments, and concentration of life-science clusters. In the Americas, established translational pipelines and a high density of pharmaceutical and biotech firms sustain demand for advanced imaging platforms and specialized reagents, with strong expectations for service support and integration into drug development workflows.
Europe, Middle East & Africa present a heterogeneous market profile where academic excellence, national research priorities, and collaborative consortia influence procurement and partnership models; here, vendors often emphasize compliance, regional servicing capabilities, and participation in public-private research initiatives. In the Asia-Pacific region, rapid expansion of research capacity, growing domestic biopharma activity, and government-backed science programs are accelerating adoption of both standalone and multimodal imaging systems, while local reagent production and regional distribution networks are becoming increasingly important to meet scaling needs.
Across all regions, the interplay of local regulatory expectations, availability of trained personnel, and logistical considerations such as reagent shelf life and instrument servicing creates distinct operational priorities. Vendors and institutional buyers that account for these regional nuances in their commercial approach and deployment models are better positioned to achieve sustained engagement and operational continuity.
Industry players building integrated ecosystems through reagent-platform-software convergence and strategic partnerships to accelerate adoption and translational credibility
Leading companies in the preclinical imaging ecosystem are differentiating through a combination of technology innovation, strategic partnerships, and expanded service offerings that bridge instrumentation, reagent chemistry, and software analytics. A prevailing strategy is to integrate reagent portfolios with imaging platforms and companion data tools to deliver turnkey solutions that reduce experimental friction and enhance reproducibility. This integration often takes the form of co-developed tracers or contrast agents validated on specific imaging systems, accompanied by certified image-analysis workflows.
Commercial players are also pursuing partnerships with academic centers, contract research organizations, and life-science hubs to accelerate validation pathways and broaden user familiarity with emerging modalities. Investment in regional service networks, training programs, and certified application laboratories helps companies lower adoption barriers and demonstrate operational support capabilities. Additionally, a trend toward modular product architectures enables incremental upgrades, protecting customer investments while allowing vendors to cross-sell software and value-added services.
Competitive differentiation increasingly rests on the ability to deliver not just hardware, but an ecosystem that includes validated reagents, interoperable software, and accessible service models that collectively support translational research needs. Companies prioritizing open interfaces, regulatory awareness, and collaborative validation stand to strengthen long-term customer relationships and clinical translational credibility.
Actionable strategic imperatives for vendors and end users to advance interoperability, reagent-platform co-development, and resilient operational models
To capture the strategic opportunities emerging in preclinical imaging, industry leaders should prioritize investment in interoperability, reagent-platform co-development, and service infrastructures that reduce adoption friction. Aligning reagent development with platform capabilities enhances signal fidelity and simplifies validation, while open software interfaces and standardized data formats enable cross-laboratory reproducibility and facilitate integration with downstream analytics.
Operationally, companies and institutional buyers should adopt a procurement mindset that balances total cost of ownership with serviceability and lifecycle upgrade pathways, ensuring that capital investments remain adaptable to evolving scientific requirements. Building regional service footprints and training curricula mitigates downtime risk and accelerates user proficiency, particularly in geographies where rapid expansion of research capacity is driving new demand. Furthermore, diversifying supplier relationships and establishing contractual protections against supply-chain volatility will help organizations preserve study continuity amid trade and logistics fluctuations.
Finally, collaborative engagement between vendors, academic centers, and CROs to co-develop use-case-driven validation studies will shorten adoption cycles and strengthen the evidentiary base for translational applications. Prioritizing these strategic actions will enable stakeholders to extract greater scientific value from imaging investments while maintaining operational resilience.
Transparent and reproducible mixed-method research approach combining stakeholder interviews, literature synthesis, and technical validation to underpin actionable insights
The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure comprehensive coverage of technological, commercial, and operational dimensions. Primary research included structured discussions with imaging scientists, procurement officers, and commercial leaders to capture real-world perspectives on platform performance, reagent selection, and service expectations. These insights were complemented by targeted interviews with laboratory managers and end users to understand workflow constraints and validation priorities.
Secondary research involved systematic review of peer-reviewed literature, regulatory guidance, vendor technical documentation, and conference proceedings to triangulate findings and contextualize emerging modality advances. Emphasis was placed on verifying claims around reagent chemistries, imaging-system capabilities, and software functionality through cross-referencing independent validation studies and manufacturer performance notes. Data synthesis prioritized reproducibility, and analytical frameworks were applied to map segmentation lenses to observable adoption drivers and operational behaviors.
Throughout the process, care was taken to document assumptions, assess potential biases, and validate conclusions with multiple stakeholder groups. The methodology is designed to be transparent and reproducible, providing a clear audit trail from raw inputs to synthesized insights that decision-makers can rely upon when shaping procurement and development strategies.
Convergent technological and operational trends positioning preclinical imaging as a pivotal enabler of translational research and experimental reproducibility
Preclinical imaging is evolving into an integrated discipline where reagents, instrumentation, and analytics are coalescing to deliver richer biological insights and more reliable translational signals. Technical advances across imaging modalities and reagent chemistries, coupled with improvements in software and data management, are enabling research teams to design experiments that speak more directly to mechanism and safety questions central to drug development and basic science inquiries.
Operational realities-such as procurement practices, service expectations, and regional supply considerations-are shaping how institutions adopt new capabilities. Stakeholders that prioritize interoperability, invest in training and service infrastructure, and engage in collaborative validation work will be best positioned to extract maximum value from technological advances. As the ecosystem matures, success will favor solutions that reduce experimental friction, enhance reproducibility, and integrate seamlessly into multi-disciplinary research programs.
In sum, the trajectory of preclinical imaging points toward greater convergence and utility, with practical implications for procurement, development strategies, and collaborative research models that collectively accelerate scientific progress.
Please Note: PDF & Excel + Online Access - 1 Year
Comprehensive orientation to the contemporary preclinical imaging ecosystem highlighting technological convergence and application-driven demand
Preclinical imaging sits at the intersection of biological discovery and instrumentation innovation, serving as a foundational pillar for translational research. Advances in imaging reagents, multimodal and standalone systems, and analytical software have expanded the capacity to visualize complex biological processes noninvasively, thereby accelerating candidate selection in drug development and refining mechanistic studies across immunology, oncology, neurology, and infectious disease research.
The field has matured from isolated modality deployments to integrated workflows in which reagents and imaging platforms are co-optimized for sensitivity, specificity, and throughput. Progressive improvements in tracer chemistry, contrast agent specificity, and image-analysis algorithms have reduced ambiguity in preclinical endpoints, enabling clearer correlations between molecular events and phenotypic outcomes. Consequently, stakeholders across academic research, contract research organizations, and industry laboratories are adapting procurement and study-design practices to extract maximum interpretive value from imaging datasets.
This report frames the contemporary preclinical imaging landscape with an emphasis on technological evolution, application-driven demands, and the operational implications for end users. The narrative avoids speculative projections, focusing instead on the observable shifts in capability and adoption that are influencing capital investment, reagent selection, and platform deployment strategies.
Emergence of integrated multimodal systems and data-driven workflows reshaping how preclinical imaging platforms and reagents are deployed
The preclinical imaging landscape is undergoing transformative shifts driven by technological convergence, data-centric workflows, and evolving end-user expectations. Multimodal integration is replacing single-modality paradigms, as researchers demand concurrent anatomical, functional, and molecular information to derive richer biological insights. This trend is supported by enhancements in core imaging modalities as well as improvements in reagents and analytical software, which together increase sensitivity and reduce interpretative uncertainty.
Simultaneously, there is a discernible shift toward modular and scalable systems that accommodate variable throughput and diverse study designs. Standalone imaging platforms remain important for focused applications, but the value proposition of multimodal systems is amplified when combined with advanced image-processing pipelines and reagent chemistries that enable cross-validation of signals. Furthermore, the proliferation of open-source and commercial software tools for image quantification and data management has elevated expectations for interoperability and reproducibility across laboratories.
Operationally, these shifts are influencing procurement cycles, study design, and collaborative models. Contract research organizations and academic cores are adapting service offerings to meet demand for integrated imaging solutions, while pharmaceutical and biotechnology companies increasingly emphasize translational fidelity in preclinical studies. The cumulative effect is a more interconnected, software-enabled imaging ecosystem that prioritizes data quality, workflow efficiency, and translational relevance.
Trade policy adjustments in 2025 influencing procurement strategies and supply chain resilience across the preclinical imaging value chain
The policy environment affecting preclinical research tools has become more intricate as trade measures and tariff schedules evolve, creating tangible implications for procurement planning and supply chain strategy. Tariff changes implemented in 2025 have altered cost structures for internationally sourced instruments and reagents, prompting laboratories and institutional buyers to reassess supplier relationships and total cost of ownership considerations.
In response to these adjustments, procurement teams are prioritizing supply chain resilience and inventory strategies to mitigate the timing and price impacts of cross-border trade measures. Vendors have likewise adjusted commercial terms, expanding regional distribution, local service footprints, and stocking arrangements to maintain competitiveness. These shifts have reinforced the importance of flexible sourcing, contractual clarity on freight and customs responsibilities, and proactive supplier risk assessment as part of capital-equipment and consumables planning.
From a strategic perspective, research organizations are balancing short-term operational continuity with longer-term considerations about localization of supply and investment in serviceable systems. The net effect is a heightened focus on supplier diversification, contractual protections, and collaborative logistics planning to preserve study timelines and maintain access to specialized reagents and instrumentation despite evolving trade conditions.
Multidimensional segmentation framework linking reagent classes, system architectures, imaging modalities, applications, and end-user requirements for strategic alignment
Detailed segmentation illuminates where value and demand converge across product, system type, imaging modality, application, and end-user profiles, enabling stakeholders to align technology choices with scientific objectives. Product-level distinctions separate reagents from software and services, with reagents encompassing bioluminescent imaging reagents, fluorescent imaging reagents, MRI contrasting reagents, PET radioactive tracers, ultrasound contrasting reagents, and X-ray CT contrasting reagents, while software and services include image analysis platforms, data management solutions, and validation services that support reproducible workflows.
System-type segmentation differentiates multimodal systems from standalone imaging systems, underscoring decisions that hinge on throughput, spatial resolution, and the necessity for correlative measurements. Imaging modality segmentation covers magnetic particle imaging, magnetic resonance imaging, micro-computed tomography, optical imaging, positron emission tomography, and single-photon emission computed tomography, each offering distinct strengths in sensitivity, spatial resolution, and target specificity that inform assay selection and study design. Application-based segmentation highlights core scientific domains-cardiology, drug development, immunology and inflammation, infectious diseases, neurology, and oncology-where imaging contributes to endpoint definition, safety profiling, and mechanism-of-action elucidation.
End-user segmentation captures the diversity of institutional needs across academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies, reflecting differences in procurement cycles, service expectations, and demands for regulatory alignment. Taken together, these segmentation lenses provide a multi-dimensional framework for mapping technology capabilities to specific experimental goals, enabling purchasers and innovators to prioritize investments that deliver operational and scientific impact.
Regional dynamics and operational considerations shaping adoption patterns and vendor engagement strategies across global preclinical imaging markets
Regional dynamics shape adoption patterns, investment priorities, and vendor strategies within the preclinical imaging landscape, driven by differences in research funding models, regulatory environments, and concentration of life-science clusters. In the Americas, established translational pipelines and a high density of pharmaceutical and biotech firms sustain demand for advanced imaging platforms and specialized reagents, with strong expectations for service support and integration into drug development workflows.
Europe, Middle East & Africa present a heterogeneous market profile where academic excellence, national research priorities, and collaborative consortia influence procurement and partnership models; here, vendors often emphasize compliance, regional servicing capabilities, and participation in public-private research initiatives. In the Asia-Pacific region, rapid expansion of research capacity, growing domestic biopharma activity, and government-backed science programs are accelerating adoption of both standalone and multimodal imaging systems, while local reagent production and regional distribution networks are becoming increasingly important to meet scaling needs.
Across all regions, the interplay of local regulatory expectations, availability of trained personnel, and logistical considerations such as reagent shelf life and instrument servicing creates distinct operational priorities. Vendors and institutional buyers that account for these regional nuances in their commercial approach and deployment models are better positioned to achieve sustained engagement and operational continuity.
Industry players building integrated ecosystems through reagent-platform-software convergence and strategic partnerships to accelerate adoption and translational credibility
Leading companies in the preclinical imaging ecosystem are differentiating through a combination of technology innovation, strategic partnerships, and expanded service offerings that bridge instrumentation, reagent chemistry, and software analytics. A prevailing strategy is to integrate reagent portfolios with imaging platforms and companion data tools to deliver turnkey solutions that reduce experimental friction and enhance reproducibility. This integration often takes the form of co-developed tracers or contrast agents validated on specific imaging systems, accompanied by certified image-analysis workflows.
Commercial players are also pursuing partnerships with academic centers, contract research organizations, and life-science hubs to accelerate validation pathways and broaden user familiarity with emerging modalities. Investment in regional service networks, training programs, and certified application laboratories helps companies lower adoption barriers and demonstrate operational support capabilities. Additionally, a trend toward modular product architectures enables incremental upgrades, protecting customer investments while allowing vendors to cross-sell software and value-added services.
Competitive differentiation increasingly rests on the ability to deliver not just hardware, but an ecosystem that includes validated reagents, interoperable software, and accessible service models that collectively support translational research needs. Companies prioritizing open interfaces, regulatory awareness, and collaborative validation stand to strengthen long-term customer relationships and clinical translational credibility.
Actionable strategic imperatives for vendors and end users to advance interoperability, reagent-platform co-development, and resilient operational models
To capture the strategic opportunities emerging in preclinical imaging, industry leaders should prioritize investment in interoperability, reagent-platform co-development, and service infrastructures that reduce adoption friction. Aligning reagent development with platform capabilities enhances signal fidelity and simplifies validation, while open software interfaces and standardized data formats enable cross-laboratory reproducibility and facilitate integration with downstream analytics.
Operationally, companies and institutional buyers should adopt a procurement mindset that balances total cost of ownership with serviceability and lifecycle upgrade pathways, ensuring that capital investments remain adaptable to evolving scientific requirements. Building regional service footprints and training curricula mitigates downtime risk and accelerates user proficiency, particularly in geographies where rapid expansion of research capacity is driving new demand. Furthermore, diversifying supplier relationships and establishing contractual protections against supply-chain volatility will help organizations preserve study continuity amid trade and logistics fluctuations.
Finally, collaborative engagement between vendors, academic centers, and CROs to co-develop use-case-driven validation studies will shorten adoption cycles and strengthen the evidentiary base for translational applications. Prioritizing these strategic actions will enable stakeholders to extract greater scientific value from imaging investments while maintaining operational resilience.
Transparent and reproducible mixed-method research approach combining stakeholder interviews, literature synthesis, and technical validation to underpin actionable insights
The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure comprehensive coverage of technological, commercial, and operational dimensions. Primary research included structured discussions with imaging scientists, procurement officers, and commercial leaders to capture real-world perspectives on platform performance, reagent selection, and service expectations. These insights were complemented by targeted interviews with laboratory managers and end users to understand workflow constraints and validation priorities.
Secondary research involved systematic review of peer-reviewed literature, regulatory guidance, vendor technical documentation, and conference proceedings to triangulate findings and contextualize emerging modality advances. Emphasis was placed on verifying claims around reagent chemistries, imaging-system capabilities, and software functionality through cross-referencing independent validation studies and manufacturer performance notes. Data synthesis prioritized reproducibility, and analytical frameworks were applied to map segmentation lenses to observable adoption drivers and operational behaviors.
Throughout the process, care was taken to document assumptions, assess potential biases, and validate conclusions with multiple stakeholder groups. The methodology is designed to be transparent and reproducible, providing a clear audit trail from raw inputs to synthesized insights that decision-makers can rely upon when shaping procurement and development strategies.
Convergent technological and operational trends positioning preclinical imaging as a pivotal enabler of translational research and experimental reproducibility
Preclinical imaging is evolving into an integrated discipline where reagents, instrumentation, and analytics are coalescing to deliver richer biological insights and more reliable translational signals. Technical advances across imaging modalities and reagent chemistries, coupled with improvements in software and data management, are enabling research teams to design experiments that speak more directly to mechanism and safety questions central to drug development and basic science inquiries.
Operational realities-such as procurement practices, service expectations, and regional supply considerations-are shaping how institutions adopt new capabilities. Stakeholders that prioritize interoperability, invest in training and service infrastructure, and engage in collaborative validation work will be best positioned to extract maximum value from technological advances. As the ecosystem matures, success will favor solutions that reduce experimental friction, enhance reproducibility, and integrate seamlessly into multi-disciplinary research programs.
In sum, the trajectory of preclinical imaging points toward greater convergence and utility, with practical implications for procurement, development strategies, and collaborative research models that collectively accelerate scientific progress.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of artificial intelligence for automated lesion detection and biomarker extraction in preclinical MRI
- 5.2. Development of high-speed volumetric ultrasound imaging systems for real-time vascular assessment in small animal models
- 5.3. Adoption of hybrid PET/MRI platforms for simultaneous functional and anatomical imaging in oncology research
- 5.4. Implementation of 3D micro-CT imaging with contrast agents for longitudinal bone density and vascular studies in rodent models
- 5.5. Advancements in fluorescence molecular tomography enabling deep tissue imaging and quantitative fluorescent probe analysis
- 5.6. Use of photoacoustic imaging combined with ultrasound to monitor tumor oxygenation and vascular changes dynamically
- 5.7. Standardization of image acquisition protocols and data normalization workflows to enhance reproducibility across preclinical sites
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Preclinical Imaging Market, by Product
- 8.1. Reagents
- 8.1.1. Bioluminescent Imaging Reagents
- 8.1.2. Fluorescent Imaging Reagents
- 8.1.3. MRI Contrasting Reagents
- 8.1.4. PET Radioactive Tracers
- 8.1.5. Ultrasound Contrasting Reagents
- 8.1.6. X-ray CT Contrasting Reagents
- 8.2. Software & Services
- 9. Preclinical Imaging Market, by Type
- 9.1. Multimodal Systems
- 9.2. Standalone Imaging Systems
- 10. Preclinical Imaging Market, by Imaging Modality
- 10.1. Magnetic Particle Imaging
- 10.2. Magnetic Resonance Imaging
- 10.3. Micro-Computed Tomography
- 10.4. Optical Imaging
- 10.5. Positron Emission Tomography
- 10.6. Single-Photon Emission Computed Tomography
- 11. Preclinical Imaging Market, by Applications
- 11.1. Cardiology
- 11.2. Drug Development
- 11.3. Immunology & Inflammation
- 11.4. Infectious Diseases
- 11.5. Neurology
- 11.6. Oncology
- 12. Preclinical Imaging Market, by End Users
- 12.1. Academic & Research Institutes
- 12.2. Contract Research Organizations
- 12.3. Pharmaceutical & Biotechnology Companies
- 13. Preclinical Imaging Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Preclinical Imaging Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Preclinical Imaging Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Advanced Molecular Vision, Inc.
- 16.3.2. Agilent Technologies, Inc.
- 16.3.3. Angstrom Advanced Inc.
- 16.3.4. Aspect Imaging Ltd.
- 16.3.5. AXT Pty Ltd
- 16.3.6. Berthold Technologies
- 16.3.7. Bruker Corporation
- 16.3.8. Cubresa, Inc.
- 16.3.9. Euro-BioImaging ERIC
- 16.3.10. FUJIFILM Holdings America Corporation
- 16.3.11. GE HealthCare Technologies Inc.
- 16.3.12. IVIM Technology Corp.
- 16.3.13. KUB Technologies, Inc.
- 16.3.14. LI-COR, Inc.
- 16.3.15. Mediso Ltd.
- 16.3.16. Milabs B.V.
- 16.3.17. Miltenyi Biotec GmbH
- 16.3.18. MR Solutions Ltd.
- 16.3.19. Peira bvba
- 16.3.20. PerkinElmer Inc.
- 16.3.21. Revvity, Inc.
- 16.3.22. Scitech Pty Ltd
- 16.3.23. Siemens AG
- 16.3.24. TriFoil Imaging
- 16.3.25. United Imaging Healthcare Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
